Targeted Medical Pharma to Present at 2013 Rodman & Renshaw Annual Global Investment Conference

Los Angeles, CA, September 5th, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that the company’s CEO and Chief Science Officer William Shell, M.D., will be presenting at the 2013 Rodman & Renshaw Annual Global Investor Conference being held at the Millennium Broadway Hotel, New York, on Monday, September 9, 2013 at 11:40 a.m. EST.

The conference will feature more than 200 public & private companies from around the world and is expected to present to an audience of over 1,500 attendees. The various tracks featured at this event include, Biotechnology/Healthcare, Technology, Natural Resources, and Growth.

According to a recent research report by Falls Church, VA-based Technology Catalysts International, the global medical foods market is estimated at approximately $12 billion and growing. The report notes that consumer and scientific interest in the relationship between diet, health, and alternative medicines has created an increased demand for medical foods.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also is engaged in the development of a proprietary line of dietary supplements.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #

Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation

Medical Food Designed to Address the Increased Nutritional Requirements of Anemia 

 

Los Angeles, CA, September 4, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced  the company has initiated a third open-label clinical trial of its oral amino acid-based erythropoietin stimulating system (ESS) to determine increased red blood cell production in subjects diagnosed with anemia of chronic disease.

The study consists of 30 patients randomized for treatment across multiple independent sites to measure the changes in blood values after the oral administration of the company’s ESS medical food.  Primary outcomes of the trial include measuring hemoglobin concentrations and hematocrit percentages, as well as calculating patients’ red blood cell counts, reticulocyte counts and IGF-1 (insulin-like growth factor) protein levels.  Subjects will be screened for enrollment based on medical history and diagnosis of anemia of chronic disease or anemia of inflammatory response.

“Earlier pilot studies of our oral ESS medical food showed a significant stimulation of progenitor stem cells, resulting in an increase in hemoglobin content in patients with chronic anemia,” said William Shell, M.D., CEO and Chief Science Officer of Targeted Medical Pharma, Inc. “Addressing specific nutrient deficiencies in this patient population with this targeted oral therapy may help promote the production of red blood cells and could potentially help the millions of people in the United States suffering from chronic and inflammatory diseases that affect erythrocyte production.”

Chronic anemia is a blood disorder that slows the production of red blood cells in the bone marrow. Various chronic infections, inflammatory diseases and other illnesses and medications can affect the body’s ability to produce red blood cells. Some of these chronic conditions include certain cancers, autoimmune diseases such as rheumatoid arthritis, as well as HIV/AIDS, hepatitis C, liver disease and heart failure.  Various symptoms of chronic anemia include fatigue and loss of energy, irregular heartbeat and shortness of breath, headaches, difficulty concentrating, dizziness and insomnia.

Targeted Medical Pharma recently announced results of an earlier pilot study that showed subjects diagnosed with mild to moderate anemia who were treated with the company’s ESS medical food increased their hemoglobin levels by an average of 11.39 percent.  The average baseline hemoglobin measurement was 10.08 and 11.21 after 45 days with a similar increase in reticulocyte count (p<0.01).

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also is engaged in the development of a proprietary line of dietary supplements.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #

Targeted Medical Pharma Develops New Medical Food for Autism Spectrum Disorders

New Product Addresses Impaired Absorption and Increased Nutritional Requirements of Autism

Los Angeles, CA, August 30, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) today announced that the company will begin a clinical trial on a new medical food indicated for the dietary management of Autism and Autism Spectrum Disorders.

This open label trial will measure the changes in blood concentrations of specific amino acids, behavior, mood, and sleep patterns over a thirty day period following a twice daily oral administration of the company’s new medical food. Subjects will be screened for enrollment based on medical history and diagnosis of Autism or any Autism Spectrum Disorders.

“Autism and Autistic Spectrum have long been recognized to be associated with reduced absorption of amino acids and a decrease in several brain neurotransmitters.  With our targeted cellular technology platform, we believe that this product may be able to increase the concentration of the necessary amino acid precursors and brain neurotransmitters that are diminshed in patients with autism,” said David Silver, M.D., President and Chief Operating Officer at Targeted Medical Pharma, Inc. “Our company has established that treating an underlying nutritional deficiency of a disease with a medical food can greatly reduce symptoms and improve clinical outcomes.”

Autism and Autism Spectrum Disorders affect one percent of the population of children in the U.S. ages three to seventeen, with an estimated prevalence of one out of eighty eight births in the U.S. being affected by the disease. The current pharmacologic treatments available are ineffective at treating the disease and are often associated with adverse side effects.

About Targeted Cellular Technology

Targeted cellular technology is a patented five-step process that is the foundation for the company’s medical foods. This technology promotes the rapid cellular uptake, conversion and release of neurotransmitter precursors, prevents attenuation and increases the efficacy of milligram quantities of amino acids, nutrients and biogenic amines.    

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also is engaged in the development of a proprietary line of dietary supplements.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #

 

Targeted Medical Pharma Establishes Dietary Supplement Division

Innovative New Products Focus on Health and Wellness

Los Angeles, August 29, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced the launch of a new division  that will specialize in the manufacturing and distribution of a proprietary line of dietary supplements.

The products, currently in the research and development phase, include a nasal decongestant, sleep aid, an appetite suppressant, a formula for pain and a formula that supports healthy cognitive performance. The products utilize the company’s patented targeted cellular technology platform to increase the effectiveness of milligram amounts of neurotransmitter precursors and “swish and swallow” system that is designed to allow digestive enzymes in saliva to initiate and facilitate digestion.

The first product is scheduled to be launched on November 1, 2013, and will be an oral dietary supplement featuring a proprietary sinuhealth blend designed to support healthy sinus and immune function, and help relieve nasal congestion, sinus pressure and runny nose associated with allergies and colds.

“We are pleased to announce the development of an over-the-counter product line and introduce a new technology that enhances the digestion processes by allowing salivary enzymes to function,” said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. “Our company is committed to innovating healthcare processes and providing physicians, patients, and health conscious consumers with the most effective and safe therapeutic options for health and wellness.”

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

#               #               #

Targeted Medical Pharma Selects William B. Horne as Chief Financial Officer

Los Angeles, August 23, 2013, Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced the appointment of William B. Horne as the company’s Chief Financial Officer.  He will oversee all aspects of the company’s fiscal operations and financial reporting.

“I am very pleased to have William join our growing management team,” said William Shell, M.D., the company’s CEO and Chief Science Officer. “His leadership and financial experience in the public and private healthcare sectors is a tremendous asset for Targeted Medical Pharma as we continue to execute on our growth strategy, driven by the increasing demand for cost-effective therapeutic alternatives such as medical foods across the healthcare sector.”

Horne brings to Targeted Medical Pharma a combination of experience in both early stage and mature environments with a 20-year record of success at managing corporate financial operations for fast-growing private and public companies.  Horne previously held the position of CFO at various companies, including OptimisCorp, a privately held healthcare technology company, and Patient Safety Technologies, Inc. (OTCBB: PSTX), a publicly traded medical device company.  He also held supervisory positions at Price Waterhouse, LLP and received a Bachelor of Arts in Accounting from Seattle University where he graduated magna cum laude.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

#     #     #

 

Targeted Medical Pharma Reports 2013 Second Quarter Financial Results

— Year-Over-Year Revenue Increase of 67% and Gross Profit  Increase

of 97% for the first half of 2013–

LOS ANGELES—August 14, 2013–Targeted Medical Pharma, Inc. (OTCQB:TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced financial results for its second quarter ended June 30, 2013. The Company continued to post increasing revenue for the second quarter and first half of 2013 compared to the second quarter and first half of 2012.

“I am thrilled to report the company’s strongest first half period as we continue to execute on our growth strategy and remain focused on increasing formulary coverage for our high value medications,” commented William Shell, M.D., Chief Executive Officer and Chief Science Officer of Targeted Medical Pharma. “The expansion and application of current initiatives, and our ability to enter new markets, coupled with an improvement in collections has resulted in increased revenue for all of our business lines. These factors contributed to our sixth consecutive quarter of revenue growth when analyzed on a year-to-year basis. I am optimistic about our growth opportunity and the team we have in place as we continue to strengthen our product pipeline and expand our sales and marketing efforts. Additionally, we continue to contain our operating expenses relative to revenue as we move toward overall profitability while we further increase our market share and enter new markets.”

Financial Overview:

Total revenue for the second quarter ended June 30, 2013 increased 32% to $1,917,388 compared to $1,448,226 in 2012. In addition, total gross profit for the quarter increased 43% to $1,181,918 in 2013 compared to $826,966 in 2012. This increase reflected a change in customer mix.

For the six months ending June 30, 2013 total revenue increased 67% to $4,728,519 compared to $2,823,411 in first half of 2012. Furthermore, total gross profit for the quarter increased 97% to $3,094,375 in 2013 compared to $1,567,416 in 2012. The loss from operations for the six months ended June 30, 2013 decreased 29% to $2,326,320 compared to the loss from operations of $3,268,229 in 2012.

“The clear implementation and precise execution of our strategy continues to exemplify itself with solid revenue and profit margin growth from operations,” said David Silver, M.D., President and Chief Operating Officer of Targeted Medical Pharma. “Along with our cost containment initiatives and tight expense control we have established a good cash flow trajectory for the Company. With clear momentum continuing to build we are expanding our sales forces to leverage unique opportunities in the marketplace and improve profitability. With further brand recognition in the medical community we are seeing increased demand from patients seeking our prescription medical foods as doctors and patients recognize the substantial benefits our products offer. As we move forward with continued development of new products, we remain focused on increasing the growth reported for the second quarter.”

First Half Highlights:

  • David Silver, M.D. promoted to President and Chief Operating Officer
  • S-1 Registration Statement declared effective by SEC
  • Expansion of private insurance market business
  • Expansion of California Worker’s Compensation market business
  • Initiation of agreements with Cambridge Medical Funding Group

Continued 2013 Strategic Initiatives:

  • Expansion of sales and marketing efforts to increase awareness and acceptance by both physicians and patients
  • Conduct additional clinical trials for current and pipeline products including Theramine®, new formulas for red blood cell production and nasal decongestion
  • Continue development of new stem cell products for neuropathy, chronic anemia, and diabetes

Detailed financial data information is available on Targeted Medical Pharma’s annual report (Form 10-Q), which is accessible on the Company’s website at www.tmedpharma.com and on the SEC’s website at sec.gov/edgar.shtml.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the United States through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides a billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Theramine® is a trademark of Targeted Medical Pharma Inc.

# # #

California Physicians Find Medical Foods Clinically Beneficial

Clinically Supported, FDA-Regulated Medications Managing Chronic Disease without Costly Side-Effects

Los Angeles, August 5th, 2013 — Prescription-only medical foods are a growing therapeutic alternative to many commonly prescribed pharmaceuticals among California physicians, according to Targeted Medical Pharma, Inc.(OTCQB:TRGM), a biotechnology company that develops these prescription medications for chronic diseases, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.

“Medical foods are shown to be safe and effective,” said Lonna Larsh, M.D., a Santa Cruz-based family physician, who recently started prescribing medical foods to her patients.  “My patients would rather not use pharmaceuticals that cause side effects and appreciate the fact that medical foods are a more natural approach to treating chronic disease and are backed by clinical evidence that shows they work.”

The medical food Theramine® is one of the medications Dr. Larsh is prescribing to her patients who suffer from chronic pain.  A clinical study published last year in the American Journal of Therapeutics found that Theramine demonstrated improvement in chronic low back pain in 129 subjects when administered as a standalone therapy or in conjunction with low dose naproxen for 28 days.  Larsh also prescribes Percura to her patients for the management of peripheral neuropathy.  Preliminary data from an open-label pilot study found that Percura reduced symptoms of pain and numbness related to peripheral neuropathy.

According to a recent research report by Falls Church, VA-based Technology Catalysts International, the global medical foods market is estimated at approximately $12 billion and growing.  The report notes that consumer and scientific interest in the relationship between diet, health, and alternative medicines has created an increased demand for medical foods.

“An increasing number of physicians in California are seeing the benefits of medical foods like Theramine and Percura for their patients either as standalone medications or used in conjunction with traditional pharmaceuticals,” said David Silver, M.D., President and Chief Operating Officer of Targeted Medical Pharma, Inc.  “Clinical studies show that medical foods are safe and effective treatments for chronic diseases without harmful side effects.”

Los Angeles-based podiatrist Dr. Gabriel J. Halperin has been prescribing medical foods to his patients to treat various pain syndromes including diabetic, peripheral and entrapped neuropathies.

“Since we started using amino acid targeted therapies [medical foods], we have cut out or reduced the need for narcotics, said Halperin.  “We are using very low doses of Cymbalta, Lyrica or Neurontin.  Prior to the use of the amino acid targeted therapies, for example, we would routinely use 800 to 1200 milligrams of Neurontin three times a day.  Now we don’t get above 300 milligrams when used alongside a medical food.”

According to Dr. Halperin, patients would rather use a natural approach for pain management.  “We’ll start the medical food for several weeks, evaluate patient progress and offer them a pharmaceutical medication only if they need it,” added Halperin. “Sometimes we use Neurontin with Theramine or Neurontin with Trepadone.  Many of the patients, however, are on medical foods only, and maybe 30 percent are on low dose neuropathy medications.”

About Targeted Medical Pharma, Inc.’s Medical Foods

Targeted Medical Pharma’s medical foods are amino acid-based, FDA-regulated medications specially formulated to meet the body’s increased nutritional requirements of certain disease states.  They are a safe and effective option for managing pain syndromes, sleep and cognitive disorders, obesity, hypertension and peripheral neuropathy without harmful side effects.  These medical foods are available by prescription only and must be administered under the ongoing supervision of a physician.  Updates on the company and these medications can be received by registering here or visiting http://www.tmedpharma.com/ir-email-alerts.php.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

 

#   #   #

Use of Prescription-Only Medical Foods Increases in Pacific Northwest and Hawaii

— 23 New Clinics Now Prescribing Targeted Medical Pharma’s Rx-only Therapeutic Alternatives —     

Los Angeles, CA, July 17, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced that 23 new medical clinics in Washington, Oregon and Hawaii are purchasing and prescribing the company’s prescription-only medical foods, bringing the total to 69 health facilities in those three states.

“With the number of prescribing clinics on the rise, we have seen a 26 percent increase in prescriptions for our medical foods in the Northwest region and Hawaii compared to last year’s fourth quarter,” said William Shell, M.D., Targeted Medical Pharma’s Chief Executive Officer and Chief Science Officer.  “Strict new regulations for opioid prescribing in Washington and Colorado coupled with widespread opposition to traditional, high dose pain drugs among patients continue to fuel the demand for safer, more effective therapeutic alternatives such as medical foods across the entire U.S.”

Targeted Medical Pharma recently posted record quarterly revenue of $2.8 million for the first quarter ended March 31, 2013, compared with $1.4 million for the prior year period, primarily attributable to a significant increase in prescriptions among Workers’ Compensation and commercial providers, along with improved collection rates for new and aged receivables.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

 

 

 

# # #

Targeted Medical Pharma Secures $3.28 Million in Funding

Agreement with Cambridge Medical Funding Group Monetizes Certain Aged  Workers’ Compensation Receivables

Los Angeles, CA, July 2, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies for the treatment of chronic disease, today announced it secured $3.28 million from the securitization of certain aged receivables through an agreement with New Jersey-based Cambridge Medical Funding Group, LLC (“CMFG”).  CMFG funded $750,000 on June 29, 2013 and  has agreed to fund the balance before July 31, 2013.

“Through this funding we are able to leverage a significant off balance sheet asset to invest in the expansion and acceleration of our sales and marketing efforts,” said William Shell, M.D., CEO and Chief Science Officer at Targeted Medical Pharma.  “The additional revenue will be used to help sustain our rapid growth as we continue to leverage the increasing clinical adoption of medical foods.”

Based in Glen Rock, New Jersey, Cambridge Medical Funding Group provides specialized finance solutions to hospitals, surgical centers and medical providers, funds receivables and providing guaranteed upfront payments to these providers.

As of June 30, 2012, Targeted Medical Pharma had approximately $34.6 million in aged receivables.  Maxim Group LLC acted as financial advisor on the transaction.

Visit http://www.sec.gov for additional details regarding the funding.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.  

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based. 

# # #

Targeted Medical Pharma Engages Marcum LLP as New Auditors

Los Angeles, CA, June 13, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced it has engaged Marcum LLP as the company’s new independent auditor.  The new accounting firm will be the signing auditor for the company’s 2013 second quarter filing.

“As we execute on our expansion strategy with the clinical adoption of medical foods growing among physicians and patients here in the U.S. and abroad, our audit needs continue to evolve as well,” said William Shell, M.D., CEO and Chief Science Officer at Targeted Medical Pharma.  “After a comprehensive review process, our audit committee decided that Marcum has the best mix of healthcare industry experience and geographic depth to meet our current and future accounting needs.”  

Based in New York City, Marcum is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum offers the resources of 1,100 professionals, including over 130 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.  

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #